期刊文献+

间充质干细胞治疗新型冠状病毒肺炎的机制及研究进展

Mechanism and research progress of mesenchymal stem cells in treatment of COVID-19
下载PDF
导出
摘要 新型冠状病毒肺炎(COVID-19)感染性强,且重型及危重型患者病死率高,缺乏特异性治疗方法,急需寻找安全有效的治疗方法。间充质干细胞(MSCs)具有免疫调节、组织修复、再生、迁移和归巢、抗病毒和抗炎等生物学特性。目前应用MSCs治疗COVID-19的研究已逐步开展。本文就2019新型冠状病毒(2019-nCoV)的致病机制、MSCs治疗COVID-19的潜在机制及面临的挑战进行综述。 Coronavirus disease 2019(COVID-19)is highly infectious,severe and critically ill patients have high mortality and lack specific treatment,so it is urgent to find safe and effective treatment methods.Mesenchymal stem cells(MSCs)have biologi-cal properties such as immune regulation,tissue repair,regeneration,migration and homing,antiviral and anti-inflammatory.At present,studies on use of MSCs in treatment of COVID-19 have been gradually carried out.This paper reviews pathogenesis of 2019 novel coronavirus(2019-nCoV),potential regulatory mechanisms and challenges of MSCs in treatment of COVID-19.
作者 凌小穗 何海萍 李凡 张丽华 LING Xiaosui;HE Haiping;LI Fan;ZHANG Lihua(Medical College of Kunming University of Science and Technology,Kunming 650500,China;Wuhu Hospital Affiliated to East China Normal University,Wuhu 241060,China)
出处 《中国免疫学杂志》 CAS CSCD 北大核心 2024年第1期220-224,共5页 Chinese Journal of Immunology
基金 国家自然科学基金地区科学基金(81760028) 云南省医学学科带头人项目(D-2018017) 芜湖市科技计划项目(2022jc75)。
关键词 间充质干细胞 新型冠状病毒肺炎 临床试验 Mesenchymal stem cells COVID-19 Clinical trials
  • 相关文献

参考文献9

二级参考文献185

  • 1沈华浩,王绍斌.布地奈德干预对卵白蛋白致敏小鼠抗原激发后气道炎症及气道重塑的影响[J].中华结核和呼吸杂志,2005,28(3):154-159. 被引量:45
  • 2Tsagias N, Koliakos i, Karagiannis V, Eleftheriadou M, Koliakos GG. Isolation of mesenchymal stem ceils using the total length of umbilical cord for transplantation purposes, Transfus Med 2011; 21: 253-261.
  • 3Liang L, DongC, Chen X, FangZ, Xu J, Liu Metal. Human umbilical cord mesenchymal stem cells ameliorate mice trinitrobenzene sulfonic acid (TNBS)-induced colitis. Cell Transplant 2011; 20: 1395-1408.
  • 4Gonzalez MA, Gonzalez-Rey E, Rico L, Buscher D, Delgado M. Adipose-derived mesenehymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses. Gastroenterology2009; 136: 978-989.
  • 5Gonzalez MA, Gonzalez-Rey E, Rico L, Buscher D, Delgado M. Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells. Arthritis Rheum 2009; 60: 1006-1019.
  • 6Nemeth K, Leelahavanichkul A, Yuen PS, Mayer B, Parmelee A, Doi K etal. Bone marrow stromal cells attenuate sepsis vie prostaglandin E2-dependent reprogramming of host macrophages to increase their interleukin-lO production. Nat Med2009; 15: 4249.
  • 7Kawada H, Fujita J, Kinjo K, Matsuzaki Y, Tsuma M, Miyatake H etal. Nonhematopoietic mesenchymal stem cells can be mobilized and differentiate into cardiomyocytes after myocardial infarction. Blood 2004; 104: 3581-3587.
  • 8Wojakowski W, Tendera M. Mobilization of bone marrow-derived progenitor cells in acute coronary syndromes. Folia Histochem Cytobiol 2005, 43: 229-232.
  • 9Chamberlain G, Fox J, Aehton B, Middleton J. Mesenchymal stem cells: their phenotype, differentiation capacity, immunological features and potential for homing. Stem Cells 2007; 25: 2739-2749.
  • 10Dazzi F, Ramasamy R, Glennie S, Jones SP, Roberts I. The role of mesenchymal stem cells in haemopoiesis. Blood Rev2006; 20: 161-171.

共引文献897

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部